CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Theriva Biologics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Theriva Biologics Inc
9605 Medical Center Drive, Suite 270
Phone: (734) 332-7800p:734 332-7800 ROCKVILLE, MD  20850  United States Ticker: TOVXTOVX
Business Summary
Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment. SYN-004 (ribaxamase) is designed to degrade certain commonly used intravenous beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage. SYN-020 is a recombinant oral formulation of the enzyme intestinal alkaline phosphatase produced under current good manufacturing practice conditions and intended to treat both local GI and systemic diseases. Its research programs include VCN-11 Albumin Shield Technology and SYN-006, SYN-007, other oncolytic virus.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202312/31/2023YesYesYes--

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Jeffrey J.Kraws 58 5/10/2012 1/1/2006
Chief Executive Officer, Chief Financial Officer, Director Steven A.Shallcross 62 12/6/2018 6/1/2015
Independent Director JohnMonahan 76 11/11/2020 11/11/2020
Independent Director Jeffrey A.Wolf 60 1/1/2006 1/1/2006

Subsidiaries
Business Name Address City State/Province Country
Hartlab LLC 391 Quadrangle Drive Bolingbrook IL United States
HealthMine, Inc. 2911 Turtle Creek Blvd. Dallas TX United States

Business Names
Business Name
CD4 Biosciences, Inc.
Effective Pharmaceuticals, Inc.
Epitope Pharmaceuticals, Inc.
10 additional Business Names available in full report.

General Information
Number of Employees: 21 (As of 3/25/2024)
Outstanding Shares: 17,148,049 (As of 3/21/2024)
Shareholders: 50
Stock Exchange: ASE
Federal Tax Id: 133808303
Fax Number: (734) 332-7878


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024